colgate optic white stain fighter with baking soda- sodium fluoride paste, dentifrice
colgate-palmolive company - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities
colgate optic white stain fighter with baking soda- sodium fluoride paste, dentifrice
colgate-palmolive company - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities
hello activated charcoal- sodium monofluorophosphate paste, dentifrice
colgate-palmolive company - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities
hello naturally whitening- sodium monofluorophosphate paste, dentifrice
colgate-palmolive company - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - anticavity helps protect against cavities
bioglan co2
bioglan laboratories ltd - betaine hydrochloride sodium bicarbonate dimethicone 350 - granules effervescent
nicholas co2 granule
nicholas laboratories - dimethicone 350 betaine hydrochloride sodium bicarbonate - gel
betaine anhydrous for solution
novitium pharma llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of majo
betaine anhydrous for oral solution- betaine anhydrous for solution
oakrum pharma, llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects
betaine anhydrous for oral solution- betaine powder, for solution
lukare medical, llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: none. risk summary available data from a limited number of published case reports and postmarketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of betaine in hum
betaine powder, for solution
cosette pharmaceuticals, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and